Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD20

CD20

Check out full-length Claudin 18.2, CD20 and more.

Brief Information

Name:B-lymphocyte antigen CD20
Target Synonym:B-lymphocyte surface antigen B1,MS4A1,B-lymphocyte antigen CD20,Membrane Spanning 4-Domains A1,Leukocyte Surface Antigen Leu-16,CD20 Antigen,CD20,Bp35,Membrane-Spanning 4-Domains Subfamily A Member 1,CD20 Receptor,LEU-16,CVID5,MS4A2,B1,S7,Antigens, CD20,Membrane-Spanning 4-Domains, Subfamily A, Member 1,B-Lymphocyte Cell-Surface Antigen B1
Number of Launched Drugs:23
Number of Drugs in Clinical Trials:81
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

CD0-H52H1-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of CD20-CAR-293 cells transfected with anti-CD20-scFv were stained with 100 μL of 3 μg/mL of Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc) (HEK293)(Cat. No. CD0-H52H1) and negative control protein respectively, washed and then followed by PE anti-His antibody and analyzed with FACS (QC tested).

CD0-H82E3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of CD20-CAR-293 cells transfected with anti-CD20-scFv were stained with 100 μL of 3 μg/mL of Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E3) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (QC tested).

CD0-C52H8-SPR
Human_FcRn_Heterodimer_Protein_SPR

Rituximab captured on CM5 chip via anti-human IgG Fc antibody can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with an affinity constant of 5.48 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

CD0-C52H8-SPR
Human_FcRn_Heterodimer_Protein_SPR

Ofatumumab captured on CM5 chip via anti-human IgG Fc antibody can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with an affinity constant of 3.51 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

MS4A1,CD20,MS4A-1

Background

B-lymphocyte antigen CD20  is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Rituximab R-105; RG-105; IDEC-102; IDEC-C2B8; RO-452294 Approved Biogen Inc 美罗华, Ristova, Rituxan, MabThera, MabThera/Rituxan EU Burkitt Lymphoma; Lymphoma, Large B-Cell, Diffuse Roche Registration Gmbh 1997-11-26 Multiple Sclerosis; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus; Nephrotic Syndrome; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Granulomatosis with Polyangiitis; Lupus Nephritis; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Rejection of liver transplantation; Microscopic Polyangiitis; Rejection of renal transplantation; Purpura, Thrombocytopenic, Idiopathic Details
Ibritumomab tiuxetan IDEC-In2B8; BAY86-5128; SHL-749; IDEC-Y2B8; IDEC-129; IDEC-2B8-MX-DTPA Approved Biogen Inc Zevalin, Zavalin Japan Lymphoma, Non-Hodgkin; Lymphoma, Mantle-Cell Mundipharma Kk 2002-02-19 Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Reliance Life Sciences) R-TPR-017 Approved Reliance Life Sciences Toritz, RituxiRel India Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid null 2016-01-01 Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Center of Molecular Immunology) Approved Center Of Molecular Immunology CIMAbior, RituxCIM Cuba Lymphoma, Non-Hodgkin null 2017-04-01 Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Biocad) BCD-020 Approved Biocad Acellbia Russian Federation Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin Biocad 2015-01-01 Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (mAbxience) RTXM-83; mAbx-02 Approved Mabxience Novex Argentina Lymphoma, Large B-Cell, Diffuse Mabxience 2015-01-01 Lymphoma, Large B-Cell, Diffuse Details
Rituximab biosimilar (Amgen) ABP-798; APB-798 Approved Amgen Inc Riabni United States Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Follicular Amgen Inc 2020-12-17 Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Pfizer) PF-05280586; PF-5280586 Approved Pfizer Pharmaceuticals Ltd (China) Ruxience EU Lymphoma, Non-Hodgkin; Pemphigus; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis Pfizer Europe Ma Eeig 2019-07-23 Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus Details
rituximab biosimilar (Zenotech) Approved Zenotech Laboratories India Lymphoma, Non-Hodgkin Zenotech Laboratories 2013-02-01 Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (AryoGen Biopharma) Approved Aryogen Biopharma Zytux Iran Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis; Microscopic Polyangiitis Aryogen Biopharma 2014-01-01 Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Shanghai Henlius Biotech) HLX-01 Approved Shanghai Henlius Biotech Co Ltd 汉利康 Mainland China Lymphoma, Non-Hodgkin Shanghai Henlius Biopharmaceuticals Co Ltd 2019-02-22 Lymphoma, B-Cell; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Intas Biopharmaceuticals) Approved Intas Biopharmaceuticals Mabtas India Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Intas Biopharmaceuticals 2013-01-01 Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Dr Reddy's Laboratories) Approved Dr. Reddy’S Laboratories Ltd Reditux, Tidecron India Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid Dr. Reddy’S Laboratories Ltd 2007-01-01 Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Biosidus) Approved Biosidus Argentina Hematologic Neoplasms Biosidus 2013-06-01 Hematologic Neoplasms Details
Rituximab biosimilar (Hetero Drugs) Approved Hetero Drugs Maball, Mabura India Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular Hetero Drugs 2015-01-01 Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Innovent Biologics) IBI-301 Approved Innovent Biologics(Suzhou) Co Ltd 达伯华, HALPRYZA Mainland China Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular Innovent Biologics(Suzhou) Co Ltd 2020-09-30 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Probiomed) PBO-326 Approved Probiomed Kikuzubam Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
Hyaluronidase/Rituximab Approved Genentech Inc Rituxan Hycela United States Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular Genentech Inc 2017-06-22 Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Celltrion) CT-P10 Approved Celltrion Truxima, Blitzima, Ritemvia, Rituzena EU Pemphigus Celltrion Healthcare Hungary Kft 2017-02-17 Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell Details
Ofatumumab OMB-157; HuMax-CD2; GSK-1841157; 2F2 Approved Genmab Arzerra, Kesimpta Mainland China Multiple Sclerosis, Relapsing-Remitting Beijing Novartis Pharma Co Ltd 2009-10-26 Multiple Sclerosis, Relapsing-Remitting; Leukemia; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Lymphoma, Follicular; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus Details
Ocrelizumab R-1594; RG-1594; PRO-70769; RO-4964913; rhuMab 2H7 Approved Genentech Inc Ocrevus EU Multiple Sclerosis Roche Registration Gmbh 2017-03-28 Multiple Sclerosis, Relapsing-Remitting; Arthritis, Rheumatoid; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Lymphoma, Non-Hodgkin Details
Obinutuzumab RG-7159; RG-7195; RO-5072759; B-HH6-B-KV1-GE; R-7159; GA-101; RG7159-7 Approved Genentech Inc Gazyva, Gazyvaro, Gazyva/Gazyvaro, 佳罗华 EU Lymphoma, Follicular F. Hoffmann-La Roche Ltd 2013-11-01 Lupus Nephritis; Carcinoma, Non-Small-Cell Lung; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Lymphoma, Follicular; Lymphoma, B-Cell; Glomerulonephritis, Membranous; Lymphoma, Large B-Cell, Diffuse; Nephrosis; Leukemia, Lymphoid; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Solid tumours Details
Rituximab biosimilar (Sandoz) GP-2013 Approved Sandoz Riximyo, Rixathon Japan Lymphoma, Non-Hodgkin; Granulomatosis with Polyangiitis; Microscopic Polyangiitis Clariant Produkte (Schweiz) Ag 2017-06-15 Granulomatosis with Polyangiitis; Lymphoma, B-Cell; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Rituximab biosimilar (CTTQ Pharma) TQB-2303 Phase 3 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) Phase 2 Clinical Southwest Hospital Chongqing Lymphoma, Large B-Cell, Diffuse Details
DI-Leu16-IL2 DI-Leu16-IL2 Phase 2 Clinical Merck Serono Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) BAT-4306F Phase 1 Clinical Bio-Thera Solutions Ltd Lymphoma, Non-Hodgkin Details
CAR-20-19-22(Medical College of Wisconsin) CAR-20-19-22 The Medical College Of Wisconsin Nonprofit Details
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics Lymphoma, B-Cell; Leukemia; Leukemia, B-Cell Details
Rituximab biosimilar (Shenzhen Main Luck Pharmaceuticals) Phase 1 Clinical Shenzhen Main Luck Pharmaceuticals Inc Arthritis, Rheumatoid; Lymphoma Details
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) Phase 1 Clinical Uclas Jonsson Comprehensive Cancer Center Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD19/CD20 CAR-T Cell Therapy (PersonGen) Phase 1 Clinical Details
CD20 CAR-T cell therapy (Shanghai Longyao Biotechnology) Phase 1 Clinical Shanghai Longyao Biological Technology Co Ltd Lymphoma, Non-Hodgkin Details
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) Phase 1 Clinical Fred Hutchinson Cancer Research Center, National Cancer Institute Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (International Biotech Center Generium) GNR-006 Phase 1 Clinical International Biotech Center Generium Lymphoma, B-Cell Details
Rituximab biosimilar (Gedeon Richter) RGB-03 Phase 1 Clinical Gedeon Richter Arthritis, Rheumatoid Details
CD19/CD20 Dual-CAR-T cell therapy (HeBei Yanda hospital) Phase 1 Clinical Hebei Yanda Hospital Lymphoma, B-Cell Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Leukemia; Lymphoma, B-Cell Details
MB-CART20.1 (Miltenyi Biotec) Phase 2 Clinical Miltenyi Biotec Lymphoma, Non-Hodgkin; Melanoma Details
Rituximab biosimilar (Boehringer Ingelheim) BI-695500 Phase 3 Clinical C.H. Boehringer Sohn Ag & Co. Kg Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) CART-20; CBM-C20.1; CBM-CD20 1 Phase 2 Clinical Pla General Hospital Leukemia; Lymphoma, B-Cell Details
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) Phase 1 Clinical First Affiliated Hospital Of Zhejiang University Lymphoma, Large B-Cell, Diffuse Details
BAT-4406F BAT-4406; BAT-4406F Phase 1 Clinical Bio-Thera Solutions Ltd Neuromyelitis Optica Details
Bendamustine Hydrochloride/Rituximab Phase 1 Clinical 1globe Biomedical Co Ltd Lymphoma, B-Cell Details
CD20-directed CAR-T cell therapy (Tongji Hospital) C-CAR066 Phase 1 Clinical Tongji Hospital Lymphoma, B-Cell Details
ACTR-707 Phase 1 Clinical Unum Therapeutics Solid tumours; Lymphoma, Non-Hodgkin; Lymphoma Details
Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) PBCAR-20A Phase 2 Clinical Precision Biosciences Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
TRS-005 TRS-005 Phase 1 Clinical Zhejiang Teruisi Pharmaceutical Inc Lymphoma, Non-Hodgkin Details
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Lymphoma, B-Cell Details
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-T Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) Phase 1 Clinical Henan Provincial Cancer Hospital Lymphoma, B-Cell Details
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) Phase 2 Clinical The Medical College Of Wisconsin Nonprofit Neoplasms Details
Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) Phase 2 Clinical Shanghai Longyao Biological Technology Co Ltd Lymphoma, Large B-Cell, Diffuse Details
Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) TRS001 Phase 1 Clinical Zhejiang Teruisi Pharmaceutical Inc Lymphoma Details
IMM-0306 IMM-0306 Phase 1 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Lymphoma, B-Cell Details
Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) Clinical Wuhan Bio-Raid Biotechnology Neoplasms Details
Ocrelizumab biosimilar (CinnaGen) Phase 3 Clinical Cinnagen Multiple Sclerosis Details
Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) Phase 3 Clinical Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Genor Biopharma) GB-241 Phase 3 Clinical Genor Biopharma Co Ltd, Nanjing Yoko Biomedical Co Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
Veltuzumab hA20; IMMU-106 Phase 2 Clinical Immunomedics Inc Lymphoma, B-Cell; Purpura, Thrombocytopenic, Idiopathic; Leukemia, Lymphoid; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Pain, Postoperative; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic Details
Rituximab conjugate (BioIntegrator) CON-4619 Phase 1 Clinical Biointegrator Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) LZM-002 Phase 1 Clinical Livzon Pharmaceutical Group Inc Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) Phase 1 Clinical Zhejiang University Hematologic Neoplasms Details
LY007 LY007 Phase 1 Clinical Shanghai Longyao Biological Technology Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
MB-106 MB-106 Phase 2 Clinical Fred Hutchinson Cancer Research Center Lymphoma, Non-Hodgkin Details
Chimeric antigen receptor T-cell therapy (Fred Hutchinson Cancer Research Center) Phase 2 Clinical Fred Hutchinson Cancer Research Center Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Fred Hutchinson Cancer Research Center) Phase 1 Clinical Fred Hutchinson Cancer Research Center Multicentric Castleman's Disease (MCD); Sarcoma, Kaposi Details
BVX20-CD20 antibody (Biocon/Vaccinex) BVX-20; BVX20-MAb Phase 2 Clinical Biocon, Vaccinex Lymphoma, Non-Hodgkin Details
Rituximab Biosimilar (Istituto Giannina Gaslini) Istituto Giannina Gaslini Details
CPO-107 Phase 2 Clinical Conjupro Biotherapeutics Inc Lymphoma, Non-Hodgkin Details
Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) LUCAR-20S Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
Divozilimab BCD-132 Phase 2 Clinical Biocad Multiple Sclerosis Details
TanCART19/20 Phase 1 Clinical The General Hospital Of The People'S Liberation Army Neuromyelitis Optica Details
MB-CART19.1 (Miltenyi Biotec) Phase 2 Clinical Miltenyi Biotec Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
C-CAR039 EXP-039; C-CAR039; C-CAR-039 Phase 1 Clinical Cellular Biomedicine Group Ltd Lymphoma, Non-Hodgkin Details
EX-103 EX-103; EX103 Phase 1 Clinical Guangzhou ASM Biomedical Technology Co Ltd Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Crosslink Pharmaceutical) B-007 Phase 1 Clinical Shanghai Crosslink Pharmaceutical R & D Co Ltd Lymphoma, Non-Hodgkin Details
Plamotamab XmAb-13676 Phase 1 Clinical Xencor Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD20 x CD3 bispecific antibody (IGM Biosciences) IGM-2323 Phase 1 Clinical Igm Biosciences Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin Details
TQB-2825 TQB-2825 Phase 1 Clinical Wuxi Biologics Co Ltd Hematologic Neoplasms Details
GB-261 GB-261 Phase 2 Clinical Genor Biopharma Co Ltd Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
SNG2005 SNG-2005 Phase 1 Clinical Alopexx Oncology Lymphoma, B-Cell Details
Rituximab/Paclitaxel AR-160 Phase 1 Clinical Mayo Clinic Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Samsung) SAIT-101 Phase 3 Clinical Samsung Biologics Arthritis, Rheumatoid; Lymphoma, Follicular Details
ADI-001 ADI-001 Phase 1 Clinical Adicet Bio Inc Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Burkitt Lymphoma; Lymphoma, Non-Hodgkin Details
1-A-46 1-A-46; CMG1A46; CMG1A-46; BR110; 1A46 Phase 1 Clinical Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd Lymphoma, Non-Hodgkin Details
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) Phase 2 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
KITE-363 KITE-363 Phase 1 Clinical Kite Pharma Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse Details
Rituximab biosimilar(Shandong New Time Pharmaceutical) H-02; F-007 Phase 3 Clinical Shandong New Time Pharmaceutical Co Ltd Lymphoma, Large B-Cell, Diffuse Details
Odronextamab REGN-1979 Phase 3 Clinical Regeneron Pharmaceuticals Inc Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
CM-355(Beijing Tiannuo Jiancheng/Connaught Biomedical Technology) CM-355 Phase 2 Clinical Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin Details
Epcoritamab GEN-3013 Phase 3 Clinical Genmab, Abbvie Inc Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Zamtocabtagene autoleucel MB-CART2019.1 Phase 2 Clinical Miltenyi Biotec Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Glofitamab RO-7082859; RG-6026 Phase 3 Clinical F. Hoffmann-La Roche Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma Details
Mosunetuzumab RG-7828; BTCT-4465A; RO-7030816 Phase 3 Clinical Genentech Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) Phase 1 Clinical Fujian Medical University Lymphoma, Large B-Cell, Diffuse Details
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) B001 Phase 1 Clinical Shanghai Pharmaceuticals Holding Co Ltd Neuromyelitis Optica; Lymphoma; Lymphoma, Non-Hodgkin Details
JMT-601 JMT-601 Phase 1 Clinical Shanghai Jinmante Biological Technology Co Ltd Lymphoma, Non-Hodgkin Details
Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) Phase 3 Clinical Shanghai Institute Of Biological Products Co Ltd Lymphoma, Large B-Cell, Diffuse Details
Rituximab biosimilar (Hualan Biological Engineering) WBP-263 Phase 3 Clinical Hualan Genetic Engineering Co Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
MRG001 MRG-001 Phase 2 Clinical Shanghai Miracogen Inc Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Lymphoma, Non-Hodgkin Details
Recombinant humanized monoclonal antibody MIL62 Phase 3 Clinical Beijing Innocare Pharma Tech Co Ltd, Beijing Mabworks Biotech Co Ltd Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message